Characterizing the Patterns of Clonal Evolution in Ibrutinib-Treated CLL: A Roadmap for Continued Progress
Dr. Wiestner highlights characteristics of ibrutinib resistant CLL as reported by Woyach and colleagues and discusses how these data refine the management of CLL in the area of targeted therapy and can stratify patients for future clinical trials.